Predominance of dense low-density lipoprotein particles predicts angiographic benefit of therapy in the Stanford Coronary Risk Intervention Project

Circulation

Volumn 94, Issue 9, 1996, Pages 2146-2153

  Miller, Bonnie D ^a   Alderman, Edwin L ^b   Haskeil, William L ^b   Fair, Joan M ^b   Krauss, Ronald M ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

angiography; atherosclerosis; coronary disease; drugs; lipoproteins

Indexed keywords

LOW DENSITY LIPOPROTEIN;

ADULT; ARTICLE; CORONARY ARTERY DISEASE; CORONARY RISK; HUMAN; LIPID METABOLISM; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; PARTICLE SIZE; PRIORITY JOURNAL; RISK ASSESSMENT;

EID: 0029823744     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.94.9.2146     Document Type: Article

References (31)

1. Haskell WL, Alderman EL, Fair JM, Maron DJ, Mackey SF, Superko HR, Williams PT, Johnstone IM, Champagne MA, Krauss RM, Farquhar JW. Effects of intensive multiple risk factor reduction on coronary atherosclerosis and clinical cardiac events in men and women with coronary artery disease: the Stanford Coronary Risk Intervention Project (SCRIP). Circulation, 1994;89:975-990.
2. Alderman EL, McMillan A, Haskell W. Effects of the lipid intervention in the Stanford Coronary Risk Intervention Project. In: Bruschke AVG, Reiber JHC, Lie KI, Wellens HJ, eds. Lipid-Lowering Therapy and Progression of Atherosclerosis. Dordrecht, Netherlands: Kluwer Academic Publishers; 1996.
3. Brown G, Albers JJ, Fisher LD, Schaefer SM, Lin JT, Kaplan C, Zhao XQ, Bisson BD, Fitzpatrick VF, Dodge HT. Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. N Engl J Med. 1990;323:1289-1298.
4. Stewart BF, Brown BG, Xiao XQ, Hillger LA, Sniderman AD, Dowdy A, Fisher LD, Albers JJ. Benefits of lipid-lowering therapy in men with elevated apolipoprotein B are not confined to those with very high low density lipoprotein cholesterol. J Am Coll Cardiol. 1994;23:899-906.
5. Kane JP, Malloy MJ, Ports TA, Phillips NR. Diehl JC, Havel RJ. Regression of coronary atherosclerosis during treatment of familial hypercholesterolemia with combined drug regimens. JAMA. 1990;264:3007-3012.
6. Watts GF, Lewis B, Brunt JNH, Lewis ES, Coltart DJ, Smith LDR, Mann JI, Swan AV. Effects on coronary artery disease of lipid-lowering diet, or diet plus cholestyramine, in the St Thomas' Atherosclerosis Regression Study (STARS). Lancet. 1992;1:563-569.
7. Blankenhorn DH, Azen SP, Kramsch DM, Mack WJ, Cashin-Hemphill L, Hodis HN, DeBoer LWV, Mahrer PR, Masteller MJ, Vailas LI, Alaupovic P, Hirsch LJ, MARS Research Group. Coronary angiographic changes with lovastatin therapy: the Monitored Atherosclerosis Regression Study (MARS). Ann Intern Med. 1993;119:969-976.
8. Hodis HN, Mack WJ, Azen SP, Alaupovic P, Pogoda JM, LaBree L, Hemphill LC, Kramsch DM, Blankenhorn DH. Triglyceride- and cholesterol-rich lipoproteins have a differential effect on mild and moderate/severe lesion progression as assessed by quantitative coronary angiography in a controlled trial of lovastatin. Circulation. 1994;90:42-49.
9. Waters D, Higginson L, Gladstone P, Kimball B, Le May M, Boccuzzi SJ, Lespérance J, CCAIT Study Group. Effects of monotherapy with an HMG-CoA reductase inhibitor on the progression of coronary atherosclerosis as assessed by serial quantitative arteriography: the Canadian Coronary Atherosclerosis Intervention Trial. Circulation. 1994;89:959-968.
10. Blankenhorn DA, Nessim SA, Johnson RL, Sanmarco ME, Azen SP, Cashin-Hemphill L. Beneficial effects of combined colestipol-niacin therapy on coronary atherosclerosis and coronary venous bypass grafts. JAMA. 1987;257:3233-3240.
11. Blankenhorn DH, Alaupovic P, Wickharn E, Chin HP, Azen SP. Prediction of angiographic change in native human coronary arteries and aortocoronary bypass grafts: lipid and nonlipid factors. Circulation. 1990;81:470-476.
12. Ornish D, Brown SE, Scherwitz LW, Billings JH, Armstrong WT, Ports TA, McLanahan SM, Kirkeeide RL, Brand RJ, Gould KL. Can lifestyle changes reverse coronary heart disease? Lancet. 1990;1:129-133.
13. Krauss RM, Blanche PJ. Detection and quanitation of LDL subtractions. Curr Opin Lipid. 1992;3:377-383.
14. Slyper AH. Low-density fipoprotein density and atherosclerosis: unraveling the connection. JAMA. 1994:272:305-308.
15. Austin MA, Breslow JL, Hennekens CH, Buring JE, Willen WC, Krauss RM. Low-density lipoprotein subclass patterns and risk of myocardial infarction. JAMA. 1988;260:1917-1921.
16. Griffin BA, Freeman DJ, Tait GW, Thomson J, Caslake MJ, Packard CJ, Shepherd J. Role of plasma triglyceride in the regulation of plasma low density lipoprotein (LDL) subfractions: relative contribution of small, dense LDL to coronary heart disease risk. Atherosclerosis. 1994;106:241-253.
17. Krauss RM. Heterogeneity of plasma low-density lipoproteins and atherosclerosis risk. Curr Opin Lipid. 1994;5:339-349.
18. Lindgren FT, Jensen LC, Hatch FT. The isolation and quantitative analysis of serum lipoproteins. In: Nelson GJ, ed. Blood Lipids and Lipoproteins: Quantitation, Composition, and Metabolism. New York, NY: John Wiley and Sons; 1972:181-274.
19. McNamara JR, Campos H, Ordovas JM, Peterson J, Wilson PWF, Schaefer EJ. Effect of gender, age, and lipid status on low density lipoprotein subfraction distribution: results from the Framingham Offspring Study. Arteriosclerosis. 1987;7:483-490.
20. Williams PT, Vranizan KM, Krauss RM. Correlations of plasma lipoproteins with LDL subfractions by particle size in men and women. J Lipid Res. 1992;33:765-774.
21. Burdon RH, Van Knippenberg PH, eds. Practice and Theory of Enzyme Immunoassays. Amsterdam, Holland: Elsevier Science Publishers; 1985:345-347; series Laboratory Techniques in Biochemistry and Molecular Biology.
22. Schumaker VN, Phillips ML, Chatterton JE. Apolipoprotein B and low-density lipoprotein structure: implications for biosynthesis of triglyceride-rich lipoproteins. Adv Protein Chem. 1994;45:205-248.
23. Ambrose JA, Tannenbaum MA, Alexopoulos D, Hjemdahl-Monson CE, Leavy J, Weiss M, Borrico S, Gorlin R, Fuster V. Angiographic progression of coronary artery disease and the development of myocardial infarction. J Am Coll Cardiol. 1988;12:56-62.
24. Little WC, Constantinescu M, Applegate RJ, Kutcher MA, Burrows MT, Kahl FR, Santamore WP. Can coronary angiography predict the site of a subsequent myocardial infarction in patients with mild-to-moderate coronary artery disease? Circulation. 1988;78:1157-1166.
25. Brown BG, Gallery CA, Badger RS, Kennedy JW, Mathey D, Bolson EL, Dodge HT. Incomplete lysis of thrombus in the moderate underlying atherosclerotic lesion during intracoronary infusion of streptokinase for acute myocardial infarction: quantitative angiographic observations. Circulation. 1986;73:653-661.
26. Ambrose JA, Winters SL, Arora RR, Eng A, Riccio A, Gorlin R, Fuster V. Angiographic evolution or coronary artery morphology in unstable angina. J Am Coll Cardiol. 1986;7:472-478.
27. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;1: 563-589.
28. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, Macfarlane PW, McKillop JH, Packard CG. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med. 1995;333:1301-1307.
29. Miller BD, Cashin-Hemphill L, Mack WJ, Hodis HN, Krauss RM. Predominance of mid-density low density lipoproteins predicts angiographic benefit of lovastatin in the Monitored Atherosclerosis Regression Study. Circulation. 1994;90(suppl I):I-460. Abstract.
30. Miller BD, Krauss RM, Cashin-Hemphill L, Blankenhorn DH. Baseline triglyceride levels predict angiographic benefit of colestipol plus niacin therapy in the Cholesterol-Lowering Atherosclerosis Study (CLAS). Circulation. 1993;4(suppl I):I-363. Abstract.
31. Gaw A, Packard CJ, Lindsay GM, Murray EF, Griffin B, Caslake MJ, Colquhoun I, Wheatley DJ, Lorimer AR, Shepherd J, Effects of colestipol alone and in combination with Simvastatin on apolipoprotein B metabolism. Arterioscler Thromb Vasc Biol. 1996;16:236-249.